RSV is frequently associated with the risk it brings to young children, but the virus also poses a high risk for adults with pre-existing health conditions and older adults. Hospitalization rates due to RSV in people with chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), coronary artery disease (CAD), asthma, and diabetes have been found to be higher than the rates in patients without these conditions.

This study aims to evaluate the safety and immune response of an investigational vaccine (mRNA-1345) aimed at preventing RSV infection in high risk adults.

Who can join this study?
Participants must meet one of the following criteria to be eligible to participate:

• Be 18 years of age or older
• Be diagnosed with at least one of the following: Coronary artery disease (CAD) or congestive heart failure (CHF), Chronic lung disease (COPD, asthma, or other,) Stable type 1 or type 2 diabetes, controlled with medication
• Not be pregnant or planning on becoming pregnant for at least 3 months following your vaccine visit

What Vaccine Will Be Given?
All participants will receive the investigational vaccine, mRNA-1345. Participants aged 18 to 59 years will be randomly assigned to a certain dose. Participants aged 60 years and older will all receive the same dose to allow for comparison.